There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on G1 Therapeutics Inc (NASDAQ: GTHX), Acelrx (NASDAQ: ACRX) and Immuron Ltd (NASDAQ: IMRN) with bullish sentiments.
G1 Therapeutics Inc (NASDAQ: GTHX)
G1 Therapeutics Inc (NASDAQ: GTHX) received a Buy rating and a $61 price target from H.C. Wainwright analyst Edward White today. The company’s shares closed on Friday at $50.06, close to its 52-week high of $52.76.
White commented:
“We are initiating coverage of Buy rating and a $61 price target based on our outlook of the company’s pipeline, which includes trilaciclib, a first-in-class drug with compelling Phase 2a data in first-line small cell lung cancer (SCLC) that is currently in three other Phase 2 trials. About 1 million patients in the U.S. receive chemotherapy annually and while the chemotherapy is typically beneficial to the patient, it damages the bone marrow and impedes the formation of blood and immune cells. Trilaciclib could improve patient outcomes by maximizing the beneficial effects of chemotherapy, while minimizing myelosuppression and immunosuppression.”
According to TipRanks.com, White is a 5-star analyst with an average return of 27.1% and a 55.4% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Synthetic Biologics Inc, and Karyopharm Therapeutics.
Currently, the analyst consensus on G1 Therapeutics Inc is Strong Buy and the average price target is $60, representing a 19.9% upside.
In a report issued on May 16, BTIG also maintained a Buy rating on the stock with a $48 price target.
See today’s analyst top recommended stocks >>
Acelrx (NASDAQ: ACRX)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Acelrx (NASDAQ: ACRX) today and set a price target of $7. The company’s shares closed on Friday at $3.20.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 20.2% and a 42.5% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Collegium Pharmaceutical, and Conatus Pharmaceuticals.
Acelrx has an analyst consensus of Moderate Buy, with a price target consensus of $4.13.
Immuron Ltd (NASDAQ: IMRN)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Immuron Ltd (NASDAQ: IMRN) today and set a price target of $20. The company’s shares closed on Friday at $8.65.
According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -2.8% and a 39.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Immuron Ltd has an analyst consensus of Moderate Buy, with a price target consensus of $20.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
